Allow states to negotiate lower prescription drug prices and extend Medicaid-negotiated discounts to low- and middle-income residents.

Chellie Pingree · Maine · Democratic

policy impact 0.70 specificity 0.86 extraction confidence 90%

Contest this claim

Occurrences

The Voluntary State Discount Prescription Drug Plan Act of 2009 would make it possible for states that negotiate for discounts under their Medicaid programs to extend those savings to anyone making up to 300% of the federal poverty level.

Pingree introduced legislation to let states extend negotiated Medicaid prescription drug discounts to low- and middle-income Americans, and said she was eager to fight drug companies to reduce prescription drug costs.

Pingree, Van Hollen introduce discount prescription drug plan | U.S. Representative Chellie Pingree
secondary · other · model gpt-5.5

Evidence

Pingree's official House biography says that, as a Maine state senator, she sponsored MaineRX, one of the nation's first prescription drug pricing bills, and that after litigation it became law.

This supports that Pingree had previously enacted a state-level prescription-drug pricing model, but it predates her federal House service and does not itself prove fulfillment of a federal campaign promise during the relevant federal term.

partial unknown A for effort

About Chellie | U.S. Representative Chellie Pingree
secondary · model gpt-5.5 · confidence 87%

Contest this evidence item

The Supreme Court syllabus describes Maine Rx as a program to reduce prescription drug prices for Maine residents by attempting to negotiate rebates with manufacturers, using Medicaid prior authorization pressure for nonparticipating companies.

The Maine Rx program closely resembles the substance of the promise: state negotiation for prescription drug discounts extending beyond Medicaid. It was a Maine state achievement, not a later federal enactment for all states.

partial unknown A for effort

Pharmaceutical Research and Mfrs. of America v. Walsh, 538 U.S. 644 (2003)
secondary · model gpt-5.5 · confidence 90%

Contest this evidence item

Congress.gov records H.R. 3 as passed by the House on December 12, 2019. The bill would have required HHS to negotiate prices for certain prescription drugs and allowed negotiated prices to be offered beyond Medicare in some circumstances.

This was concrete later federal action on drug-price negotiation, but it centered on HHS and Medicare/private insurance rather than allowing states to negotiate Medicaid-linked discounts for low- and middle-income residents. It also did not become law.

partial later_term A for effort

H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act, 116th Congress
secondary · model gpt-5.5 · confidence 86%

Contest this evidence item

The Clerk records Roll Call 682 on H.R. 3 as passed, 230-192, on December 12, 2019; the roll-call listing records Rep. Chellie Pingree of Maine voting Yea.

Pingree voted for a major House drug-price negotiation bill, showing concrete effort. Because the bill did not become law and did not match the state Medicaid-discount mechanism, this is effort but not full delivery.

partial later_term A for effort

Roll Call 682 | Bill Number: H.R. 3 | Office of the Clerk, U.S. House
secondary · model gpt-5.5 · confidence 88%

Contest this evidence item

Congress.gov records H.R. 5376 as Public Law 117-169. The law created Medicare prescription-drug negotiation and inflation rebate provisions, not a state Medicaid-discount extension program for low- and middle-income residents.

The Inflation Reduction Act delivered part of the broader policy goal, namely federal Medicare drug-price negotiation, during Pingree's later House service. It did not fulfill the specific promise to let states negotiate and extend Medicaid-negotiated discounts to non-Medicaid low- and middle-income residents.

partial later_term A for effort

H.R.5376 - Public Law No. 117-169
secondary · model gpt-5.5 · confidence 84%

Contest this evidence item

Congress.gov identifies Chellie Pingree as a House member from Maine's 1st District from the 111th through 119th Congresses, beginning in 2009.

This establishes the relevant later federal service window for assessing post-campaign congressional action. The available federal record shows partial drug-price negotiation advances, but not enactment of the specific state Medicaid-discount promise.

partial unknown

Representative Chellie Pingree | Congress.gov
secondary · model gpt-5.5 · confidence 90%

Contest this evidence item

Assessments

partial later_term A for effort

The specific federal promise was not fully delivered: no enacted federal program broadly allowed states to negotiate prescription drug prices and extend Medicaid-negotiated discounts to low- and middle-income non-Medicaid residents. Pingree had earlier state-level credit for Maine Rx, which resembled the policy, and later supported major federal drug-pricing efforts including H.R. 3. The Inflation Reduction Act later enacted Medicare drug-price negotiation and rebate provisions, advancing part of the broader prescription-drug affordability goal but not the state Medicaid-discount mechanism promised.

provider codex_cli · model gpt-5.5 · confidence 86%